Výsledky vyhledávání - "Tara, Muijlwijk"

Akademický článek

Hallmarks of a genomically distinct subclass of head and neck cancer

Autor: Tara Muijlwijk, Irene H. Nauta, Anabel van der Lee, Kari J. T. Grünewald, Arjen Brink, Sonja H. Ganzevles, Robert J. Baatenburg de Jong, Lilit Atanesyan, Suvi Savola, Mark A. van de Wiel, Laura A. N. Peferoen, Elisabeth Bloemena, Rieneke van de Ven, C. René Leemans, Jos B. Poell, Ruud H. Brakenhoff

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)

Abstract Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these copy number changes are key characteristics of cancer development. Nonetheless, some tumors show hardly any CNAs, a remarka

Externí odkaz: https://doaj.org/article/225436245a4a4f2badda609a77918405

Zobrazit plný text záznamu

Akademický článek

Immune cell topography of head and neck cancer

Autor: Bernard A Fox, Rieneke van de Ven, Carmen Ballesteros-Merino, Tara Muijlwijk, Sonja H Ganzevles, Ruud H Brakenhoff, Jos B Poell, Dennis N L M Nijenhuis, C René Leemans, Laura A N Peferoen, Elisabeth Bloemena, Fatima Ekhlas

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)

Background Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20% of patients respond.

Externí odkaz: https://doaj.org/article/706241e19a784c6ebfc691493690aafb

Zobrazit plný text záznamu

Akademický článek

Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites

Autor: Bernard A Fox, Rieneke van de Ven, Yoshinobu Koguchi, Venkatesh Rajamanickam, Tara Muijlwijk, Sonja H Ganzevles, Ruud H Brakenhoff, Arjen Brink, Changlin Ke, Joseph N Fass, Jos B Poell, Dennis N L M Nijenhuis, C René Leemans

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)

Background The response rate to immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) receptor is 13%–18% for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Detailed understanding of the tumor i

Externí odkaz: https://doaj.org/article/4c0703b158e44abebdb94f559e449d18

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání